LONDON--(BUSINESS WIRE)--As one of the leading causes of death on a global basis, safe and effective treatment for sepsis - an uncontrolled immune response to infection, or injury - is in high demand. The condition does not discriminate, and is on the rise in hospital surroundings. By 2017 it is expected that the sepsis therapeutics market will attain a value of $103 million, according to a new report available on companiesandmarkets.com.
Sepsis Therapeutics: A Global Strategic Business Report
A highly complex disease, sepsis is notoriously difficult to treat and has limited treatment options. Only one drug, Xigris, is currently approved for sepsis treatment, although Eli Lilly has reported declining sales in recent years. Despite the high mortality rate and increasing incidence of sepsis, the interest from the pharmaceutical industry is still fairly low, with several companies having pulled out of expensive late stage clinical trials because of poor efficacy.
Traditional sepsis treatments include: Corticosteroids, immunoglobulins and anticoagulants.
The following types of sepsis are analysed within the research report: SIRS, Uncomplicated Sepsis, Severe Sepsis, Septic Shock, Septicemia / Septicaemia and Bacteremia.
Clinicians are noting rising resistance to antibiotics used to treat infections before they become a form of sepsis, which will also exacerbate demand for sepsis therapies. The use of exploratory surgery and interventional procedures is also on the rise, increasing potential opportunities for infection.
Over thirty sepsis market participants are profiled within the report, including Agennix AG, Atox Bio Inc, Eli Lilly and Company, NexBio Inc., AstraZeneca Plc, CytoGenix Inc., Endacea Inc. and Medinox Inc.
Published in August 2011, the 188 page research piece investigates the market for sepsis drugs, with historical and forecast data for the period 2003-2017. The sepsis therapeutics report focuses closely on the US market and provides summary information for the rest of the world. It also includes detailed information on existing and potential sepsis drug molecules and strategic corporate developments.
Report Details: